Advancing Precision Cancer Care – Atlanta will bring together leading oncology and pathology experts from across the Southeastern United States to explore the latest innovations in biomarker-driven diagnostics, molecular profiling, and targeted cancer therapies. Scheduled for May 1, 2026, this educational program will highlight how precision medicine is reshaping cancer diagnosis, treatment strategies, and clinical research.
Hosted in collaboration with City of Hope Cancer Center Atlanta, the program is part of the regional Advancing Pathology Education (APE) and Advancing Precision Oncology (APO) initiatives. These programs aim to foster collaboration between oncologists, pathologists, and multidisciplinary specialists while promoting the integration of advanced diagnostic technologies into routine oncology practice.
Atlanta is rapidly emerging as a hub for medical innovation and patient-centered oncology care. With leading academic institutions, research hospitals, and biotechnology organizations based in the region, the city provides an ideal setting for discussions focused on the future of precision medicine and the diagnostic-to-treatment continuum in cancer care.
The meeting will be chaired by Debora Bruno, MD, MS, thoracic medical oncologist and Medical Director of Clinical Research at City of Hope Cancer Center Atlanta. Dr. Bruno is widely recognized for her leadership in thoracic oncology and for advancing innovative clinical trials focused on lung cancer and other thoracic malignancies. Under her guidance, the program will explore how biomarker-guided diagnostics and targeted therapies are improving outcomes for patients across multiple cancer types.
Throughout the day, experts from leading institutions will present sessions covering several major areas of oncology, including breast cancer, lung cancer, colorectal cancer, pancreatic cancer, prostate cancer, and hematologic malignancies. These presentations will address the rapidly evolving role of molecular diagnostics, biomarker methodologies, and translational research in guiding clinical decision-making.
Participants will gain insights into how emerging diagnostic technologies enable clinicians to identify actionable mutations, select targeted therapies, and personalize treatment strategies for individual patients. Discussions will also highlight the importance of collaboration between pathology and oncology teams to ensure that biomarker testing and precision diagnostics are effectively integrated into clinical workflows.
The program agenda includes keynote presentations, scientific sessions, networking opportunities, and panel discussions with specialists from major academic and clinical centers. Topics will range from advances in breast and lung cancer biomarkers to emerging therapies for acute leukemias and myeloma, as well as innovative approaches to addressing health disparities in high-risk populations.
One of the highlights of the event will be a Targeted Therapies in Lung Cancer panel discussion, where leading oncologists will examine the latest treatment strategies and explore how molecular profiling is transforming lung cancer management.
This complimentary CME-accredited educational program is designed for oncologists, pathologists, clinical researchers, and healthcare professionals involved in cancer diagnosis and treatment. By bringing together experts from hospital systems, research centers, and academic institutions, the event aims to strengthen interdisciplinary collaboration and accelerate the adoption of precision oncology practices.
Ultimately, Advancing Precision Cancer Care – Atlanta 2026 reflects the growing commitment within the medical community to deliver more personalized, data-driven cancer care. By connecting diagnostic innovation with therapeutic advances, precision medicine continues to move oncology toward a future where every patient receives treatments tailored to their unique biological profile.